Literature DB >> 20838750

The inter-rater reliability of the Pulmonary Embolism Severity Index.

Montserrat Fraga1, Patrick Taffé, Marie Méan, Olivier Hugli, Stéphanie Witzig, Gérard Waeber, Drahomir Aujesky.   

Abstract

The Pulmonary Embolism Severity Index (PESI) is a validated clinical prognostic model for patients with acute pulmonary embolism (PE). Our goal was to assess the PESI's inter-rater reliability in patients diagnosed with PE. We prospectively identified consecutive patients diagnosed with PE in the emergency department of a Swiss teaching hospital. For all patients, resident and attending physician raters independently collected the 11 PESI variables. The raters then calculated the PESI total point score and classified patients into one of five PESI risk classes (I-V) and as low (risk classes I/II) versus higher-risk (risk classes III-V). We examined the inter-rater reliability for each of the 11 PESI variables, the PESI total point score, assignment to each of the five PESI risk classes, and classification of patients as low versus higher-risk using kappa (κ) and intra-class correlation coefficients (ICC). Among 48 consecutive patients with an objective diagnosis of PE, reliability coefficients between resident and attending physician raters were > 0.60 for 10 of the 11 variables comprising the PESI. The inter-rater reliability for the PESI total point score (ICC: 0.89, 95% CI: 0.81-0.94), PESI risk class assignment (κ: 0.81, 95% CI: 0.66-0.94), and the classification of patients as low versus higher-risk (κ: 0.92, 95% CI: 0.72-0.98) was near perfect. Our results demonstrate the high reproducibility of the PESI, supporting the use of the PESI for risk stratification of patients with PE.

Entities:  

Mesh:

Year:  2010        PMID: 20838750     DOI: 10.1160/TH10-07-0426

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Authors:  Gregory J Fermann; Petra M G Erkens; Martin H Prins; Philip S Wells; Ákos F Pap; Anthonie W A Lensing
Journal:  Acad Emerg Med       Date:  2015-02-25       Impact factor: 3.451

3.  Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients.

Authors:  June Palmer; George Bozas; Andrew Stephens; Miriam Johnson; Ged Avery; Lorcan O'Toole; Anthony Maraveyas
Journal:  BMC Health Serv Res       Date:  2013-06-27       Impact factor: 2.655

4.  Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report.

Authors:  Maurizio Menichetti; Sebastiano Rosso; Elisa Menegatti; Maria Pazzaglia
Journal:  J Med Case Rep       Date:  2015-11-26

Review 5.  Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis.

Authors:  Antoine Elias; Susan Mallett; Marie Daoud-Elias; Jean-Noël Poggi; Mike Clarke
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.